Consent beyond the written form: Implications for ketamine trials in the Philippines.
Ther Adv Psychopharmacol August 31, 2026
Consent beyond the written form: Implications for ketamine trials in the Philippines.
Ther Adv Psychopharmacol
ISSN 2045-1253; 2045-1261;
10 papers in the library · 56 citations · publishing 2014-2026
Papers
Readability of informed consent forms from ClinicalTrials.gov in ketamine clinical trials for mental health conditions: a cross-sectional analysis.
Ther Adv Psychopharmacol June 29, 2026 Damian Swieczkowski, Aleksander Kwaśny, Wiesław Jerzy Cubała
Readability of informed consent forms from ClinicalTrials.gov in ketamine clinical trials for mental health conditions: a cross-sectional analysis.
Early suicidal ideation change and suicidality-associated emergency department utilization after ketamine or esketamine treatment in treatment-resistant depression.
Ther Adv Psychopharmacol May 22, 2026 Liliana Patarroyo-Rodriguez, Vanessa K. Pazdernik, Jennifer L. Vande Voort et al.
Early suicidal ideation change and suicidality-associated emergency department utilization after ketamine or esketamine treatment in treatment-resistant depression.
Corrigendum to "Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study".
Ther Adv Psychopharmacol May 19, 2026 correction
Corrigendum to "Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study".
From model psychosis to rapid antidepressant: a historical and conceptual review of ketamine's psychiatric history.
Ther Adv Psychopharmacol December 11, 2025 Casimiro Cabrera Abreu, Aleksandar Biorac, Ross J. Baldessarini et al.
Ketamine’s development in psychiatry exemplifies the evolution of psychopharmacology over six decades. Originally introduced as a dissociative anesthetic and psychotomimetic probe, ketamine has been repositioned as a rapidly acting antidepressant, particularly for treatment-resistant depression (TRD). This narrative review draws on historical sources, clinical trials, regulatory documents, and...
Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine.
Ther Adv Psychopharmacol December 4, 2025 Charles Dodds, Rachelle Dawson, Alexander Lim et al. 3 citations
Novel interventions for post-traumatic stress disorder (PTSD) leverage the psychoactive properties of psychedelic compounds, such as ketamine, 3,4-methylenedioxymethamphetamine and psilocybin, which may overcome limitations of conventional treatments. Through the modulation of pathways involved in synaptic plasticity, psychedelic interventions are believed to enhance the mechanisms underlying...
What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial.
Ther Adv Psychopharmacol December 4, 2025 Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner et al.
What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial.
Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review.
Ther Adv Psychopharmacol October 16, 2025 Stanley Wong, Brett D. M. Jones, Mathura T. Thiyagarajah et al. 3 citations
Background: Results from contemporary clinical trials of serotonergic psychedelic therapies have led to an increasing focus on their potential clinical use across mental disorders. However, studies examining mechanisms of clinical response to psychedelic therapy in psychiatric populations are limited. This review aimed to synthesize evidence from studies examining biomarkers of clinical...
Psychedelics and virtual reality: parallels and applications.
Ther Adv Psychopharmacol August 14, 2020 Jacob S. Aday, Christopher C. Davoli, Emily K. Bloesch 50 citations
Psychedelic drugs and virtual reality (VR) each have the capacity to disrupt the rigidity and limitations of typical conscious experience. This article delineates the parallels among psychedelic and VR states as well as their potential synergistic applications in clinical and recreational settings. Findings indicate that, individually, psychedelics and VR are used in analogous ways to alter...
Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles.
Ther Adv Psychopharmacol August 1, 2014
Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles.